Market Research Logo

Spasticity - Pipeline Review, H1 2015

Spasticity - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Spasticity - Pipeline Review, H1 2015’, provides an overview of the Spasticity’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Spasticity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Spasticity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Spasticity Overview
Therapeutics Development
Pipeline Products for Spasticity - Overview
Pipeline Products for Spasticity - Comparative Analysis
Spasticity - Therapeutics under Development by Companies
Spasticity - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Spasticity - Products under Development by Companies
Spasticity - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Canbex Therapeutics Ltd.
Concert Pharmaceuticals, Inc.
Daewoong Pharmaceutical Co., Ltd.
Echo Pharmaceuticals B.V.
GW Pharmaceuticals plc
Ipsen S.A.
Merz Pharma GmbH & Co. KgaA
OBI Pharma, Inc.
Osmotica Pharmaceutical Corp.
Sanochemia Pharmazeutika AG
SciFluor Life Sciences, LLC
Sun Pharma Advanced Research Company Ltd.
Spasticity - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abobotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arbaclofen ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
baclofen ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CTP-354 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nabiximols - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-2221 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OBI-858 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Spasticity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tolperisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VSN-16R - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spasticity - Recent Pipeline Updates
Spasticity - Dormant Projects
Spasticity - Discontinued Products
Spasticity - Product Development Milestones
Featured News & Press Releases
Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults
Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients
Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly
Oct 13, 2014: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity
Jul 16, 2014: Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity
Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe
Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul
Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity
Oct 02, 2013: GW Pharmaceuticals Announces New Sativex Data at ECTRIMS
Aug 14, 2013: GW Pharmaceuticals Opens an Investigational New Drug Application in the United States for a Sativex Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Spasticity, H1 2015
Number of Products under Development for Spasticity - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Spasticity - Pipeline by Addex Therapeutics Ltd, H1 2015
Spasticity - Pipeline by Canbex Therapeutics Ltd., H1 2015
Spasticity - Pipeline by Concert Pharmaceuticals, Inc., H1 2015
Spasticity - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015
Spasticity - Pipeline by Echo Pharmaceuticals B.V., H1 2015
Spasticity - Pipeline by GW Pharmaceuticals plc, H1 2015
Spasticity - Pipeline by Ipsen S.A., H1 2015
Spasticity - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015
Spasticity - Pipeline by OBI Pharma, Inc., H1 2015
Spasticity - Pipeline by Osmotica Pharmaceutical Corp., H1 2015
Spasticity - Pipeline by Sanochemia Pharmazeutika AG, H1 2015
Spasticity - Pipeline by SciFluor Life Sciences, LLC, H1 2015
Spasticity - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Spasticity Therapeutics - Recent Pipeline Updates, H1 2015
Spasticity - Dormant Projects, H1 2015
Spasticity - Dormant Projects (Contd..1), H1 2015
Spasticity - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Spasticity, H1 2015
Number of Products under Development for Spasticity - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report